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The purpose of this study was to determine the prognostic significance of a high pretreatment serum CYFRA 21-1 level (a cytokeratin
19 fragment) adjusted for the effects of well-known co-variables in non-small-cell lung cancer (NSCLC). This meta-analysis based on
individual updated data gathered comprehensive databases from published or unpublished controlled studies dealing with the
prognostic effect of serum CYFRA 21-1 level at presentation in NSCLC of any stage (nine institutions, 2063 patients). Multivariate
regression was carried out with the Cox model. The proportional hazard assumption for each of the selected variables retained in the
final model was originally checked by log minus log plots baseline hazard ratio. The follow-up ranged from 25 to 78 months. A total of
1616 events were recorded. In the multivariate analysis performed at the 1-year end point, a high pretreatment CYFRA 21-1 level
was an unfavourable prognostic determinant in all centres except one (Hazard ratio (95% confidence interval): 1.88 (1.64–2.15),
Po10
 4). Other significant variables were stage of the disease, age and performance status. Within the first 18 months, the
procedure disclosed a nearly similar hazard ratio for patients having a high pretreatment serum CYFRA 21-1 level (1.62 (1.42–1.86),
Po10
 4). For patients who did not undergo surgery, the hazard ratio during the first year of follow-up was 1.78 (1.54–2.07),
Po10
 4. Finally, in the surgically treated population, at the 2-year end point, a high pretreatment CYFRA 21-1 and a locally advanced
stage remained unfavourable prognostic determinants. In conclusion CYFRA 21-1 might be regarded as a putative co-variable in
analysing NSCLC outcome inasmuch as a high serum level is a significant determinant of poor prognosis whatever the planned
treatment.
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Treatment of non-small-cell lung cancer (NSCLC) is probably one
of the great challenges of medical oncology owing to an increasing
incidence in both men and women and poor prognosis (Ihde et al,
1997). Therapy of this disease remains experimental in many
settings such as optimal chemotherapy combinations for the
advanced stages. One of the difficulties in interpreting clinical
trials and establishing treatment guidelines consists in the
considerable heterogeneous clinical behaviour of this disease.
Hitherto, the prognosis was mainly defined by three variables: the
stage of the disease (Inoue et al, 1998; Andre et al, 2000), the
performance status (Firat et al, 2002) and different patient
conditions including age (Merrill et al, 1999). Although the
negative impact of male gender remains debatable (Keller et al,
2002), gender is usually considered as an important variable and
included in the stratification process of large randomised phase III
trials (Schiller et al, 2002). This latter variable is not universally
recognised as a prognostic factor, particularly in Europe where the
female gender represents less than 30% of the population. Up till
now, most of the randomised studies of chemotherapy in this
disease are stratified on stage, performance status, and, incon-
stantly, presence of brain metastasis and weight loss (Scagliotti
et al, 2002; Schiller et al, 2002). It is expected that such
stratification avoids the imbalance of main prognostic variables
between different treatment groups. However, the part of
uncertainty remains high due to the great heterogeneity of tumour
behaviour between groups defined according to the aforemen-
tioned variables. Thus, an awareness of significant variables able to
predict poor prognosis is needed.
Several attempts at introducing biological variables into the
‘prognostic equation’ of NSCLC found different limits. Although
some routine biological abnormalities such as elevated alkaline
phosphatase, elevated lactate dehydrogenase, hyperleukocytosis or
hyponatremia are well-known prognostic determinants in the
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lsetting of small-cell lung cancer (Cerny et al, 1987), their ability to
predict patient outcome in NSCLC is inconsistently reported from
one study to another (Paesmans et al, 1995b; Quoix and Moreau,
2000). On the other hand, sophisticated genetic abnormalities such
as ploidy (Choma et al, 2001), p53 mutations (Steels et al, 2001),
bcl-2 protein overexpression (Gaffney et al, 1994) need complex
sample processes and techniques in order to detect a single
abnormality.
Among the different biological markers that describe the NSCLC
phenotype, one can consider the case of cytokeratin serum
detection as a putative way to help in determining prognosis
(Pujol et al, 1993a). As intermediate filaments of the epithelial
lineage, cytokeratins indicate an epithelial differentiation. In
addition, they might reflect the tumour growth fraction. Regarding
the latter potential usefulness, tissue polypeptide antigen has been
described as a human antigenic protein released immediately after
mitosis (Bjo ¨rklund et al, 1987). A cytokeratin is a heterotypic
tetramer of protofilaments composed of two polypeptides: one
acidic type I subunit and one basic type II subunit. Each type of
epithelia and their malignant counterpart express a specific
cytokeratin polypeptide pattern (Moll et al, 1982, 1983). Simple
epithelia, including pseudostratified epithelia such as the respira-
tory one, express cytokeratin 7, 8, 18 and 19. One of the most
extensive experiences in this field is the use of tissue polypeptide
antigen (TPA). Independent studies suggest that this marker is
related to tumour mass and indicates a poor prognosis (Salvati
et al, 1985; Buccheri and Ferrigno, 1989). However, immunological
mapping has revealed that TPA contains 35 epitopes (Bjo ¨rklund
et al, 1987). Selective antibodies raised against simple epithelium
type cytokeratin, particularly the acidic (type I) subunit cytoker-
atin 19, have been shown to react with all histologies of lung
cancers (Debus et al, 1984). A fragment of cytokeratin subunit 19
corresponding to epitope sequences lying within the sequences
311–335 and 346–367 (Bodenmu ¨ller et al, 1994) can be measured
in serum by a sandwich assay, CYFRA 21-1, using two mouse
monoclonal antibodies, KS 19-1 and BM 19–21.
CYFRA 21-1 has been extensively evaluated in the setting of
NSCLC. This immunoradiometric test is well standardised and
recognises a well-characterised cytokeratin 19 sequence. In
addition, the sampling is not invasive and can be reproduced
during follow-up. Interesting literature is emerging regarding the
genetic regulation of cytokeratin 19 mRNA expression with
differences from cell line to cell line (Ueda et al, 1999).
Independent clinical groups have observed a similar negative
prognostic effect of a high pretreatment serum CYFRA 21-1 level in
NSCLC patient outcome.
By analysing the different prognostic studies (Ebert et al, 1993,
1997; Pujol et al, 1993a, 1996, 2001a; Giovanella et al, 1995; Moro
et al, 1995; Paesmans et al, 1995a; Wieskopf et al, 1995;
Szturmowicz et al, 1996; Brechot et al, 1997; Hamzaoui et al,
1997; Takei et al, 1997; Hirashima et al, 1998; Niklinski et al, 1998;
Nisman et al, 1998, 1999; Foa et al, 1999; Kashiwabara et al, 2000;
Buccheri et al, 2003), one can observe that there are some
uncertainties regarding the exact hazard ratio of risk of death
associated with a high serum CYFRA 21-1 level insofar as the
estimated values range from 1.05 (Moro et al, 1995) to 2.8
(Wieskopf et al, 1995). This discrepancy is puzzling and might
reflect both the relatively small size of the studies and the
inconstancy of co-variables introduced in the proportional hazards
model. For instance, the 1.41 hazard ratio reported in the recently
updated Montpellier study (Pujol et al, 2001a) comprised a narrow
95% confidence interval (1.15–1.73) owing to the large population
in which it was established. Therefore, we organised a meta-
analysis of studies dealing with the estimation of the prognostic
effect of CYFRA 21-1 in NSCLC. This meta-analysis aimed at
defining, in over 2000 patients, the risk of death hazard ratio
associated with a high serum CYFRA 21-1 level taking into account
other main co-variables known as prognostic factors.
TRIALS AND METHODS
Eligibility criteria
This meta-analysis gathered complete and comprehensive data-
bases from published or unpublished controlled studies dealing
with the prognostic effect of pretreatment serum CYFRA 21-1
levels in NSCLC at any stage. Individual updated data have been
used from all participating institutions.
To be accrued in the study each individual patient had to fulfil
the following criteria: (1) histologically proven NSCLC according
to the current World Health Organisation pathologic description
of malignant tumours (World Health Organisation, 1999) in
samples obtained either by bronchoscopy biopsies or fine needle
trans-parietal biopsies or mediastinoscopy or any other sampling
of metastases; (2) determination of stage grouping according to the
following minimal staging procedure: clinical examination, stan-
dard chest roentgenography, computed tomographic (CT) scan of
chest and upper abdomen (bone scanning and brain CT-scan were
systematically applied in some centres only); (3) initial perfor-
mance status (Zubrod et al, 1960) established according to the
Eastern Cooperative Oncology Group (ECOG) scale (converted
from Karnofsky index in one institution); (4) minimal description
of the initial treatment that was dichotomously defined as surgery
versus medical treatment (i.e. chemotherapy, radiotherapy, best
supportive care or a combination of these therapies), and finally,
(5) serum CYFRA 21-1 level as determined using either
immunoradiometric assay or enzyme-linked immunosorbent assay
prior to any therapy. Pooling data obtained via these two different
techniques has been considered as methodologically valid insofar
as the formal comparison of the results tightly correlated: 0.99
coefficient correlation after logarithmic transformation (Van Der
Gaast et al, 1994).
Selection of publications
A computerised bibliography was extracted from MEDLINE and
CANCERLIT (CancerNett) databases using medical subject head-
ings for the following terms: lung neoplasm, lung carcinoma, non-
small-cell, CYFRA 21-1, cytokeratin 19, and prognosis. The search
for publications in any language was carried out from 1993, date of
first prognostic study on CYFRA 21-1 (Pujol et al, 1993a), to 2001
inclusive. Afterwards, the manual selection of relevant studies was
based upon summary analysis. The reprint of each study was
carefully analysed regarding the different eligibility criteria. In
addition to the aforementioned procedure, bibliographies of
selected full papers were screened in order to disclose other
relevant articles. Repeated publications regarding the same
database were listed and the analysis was restricted to the most
recent one (e.g. reference Pujol et al, 2001a for Pujol et al, 1993a,
1996, 2001a). The authors of each publication were invited to
participate in this meta-analysis based on individual data. In
addition to the literature search, some centres were directly
contacted because they were renowned for working in the field of
prognostic impact of cytokeratin markers in NSCLC. Most of them
have presented their results as an abstract or a lecture during
conferences but did not formally publish them until now. In
addition, in 2001, the Lung Cancer journal published a letter by the
Montpellier thoracic oncologic group advising that a meta-analysis
based on individual data from all studies dealing with the
estimation of CYFRA 21-1 as a prognostic determinant in this
disease was ongoing and inviting all investigators interested in this
project to participate (Pujol et al, 2001b).
The research procedure identified 16 putative centres that have
communicated or published on the subject. Among the 16 centres
contacted, 11 responded but only nine of them were able to
produce a comprehensive database. Most of the studies have been
published apart, some of them more than once. The total accrual of
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lthese centres represented a population of 2063 patients suffering
from NSCLC (Table 1). Therefore, the population of the present
meta-analysis consisted of 73% of the estimated accrual of all trials
whatever the methodology and reliability of database. The
estimated cumulative population, not included in the meta-
analysis measured by using the reported patient numbers in the
methods section of the publications, was 764 patients. This
represents seven studies and eight publications (Giovanella et al,
1995; Takei et al, 1997; Hirashima et al, 1998; Niklinski et al, 1998;
Nisman et al, 1998, 1999; Foa et al, 1999; Kashiwabara et al, 2000;
Table 2), all of them having reported a poor prognostic outcome
for patients presenting with a high serum CYFRA 21-1 level,
confirmed by multivariate analysis in four instances (Hirashima
et al, 1998; Niklinski et al, 1998; Nisman et al, 1998, 1999; Foa et al,
1999).
Collecting databases
On site help in preparing the data was provided by one author
(OM) whenever this direct support was required. Each centre
provided an updated database with the following variables: (1)
centre number, (2) identification number of the patient in the
centre, (3) gender, (4) age at time of diagnosis, (5) date of
pretreatment CYFRA 21-1 sampling taken as the date of origin, (6)
date of last contact, (7) status at last contact, (8) performance
status, (9) staging carried out by standard procedures according to
the 4th edition of the Union Internationale Contre le Cancer
(UICC) tumour node metastases (TNM) classification (Tisi et al,
1982), the American Thoracic Society map of regional pulmonary
nodes (Sobin et al, 1987) and the new Mountain stage grouping
(Mountain, 1997), (10) histological subgroup (World Health
Organisation, 1999), (11) pretreatment CYFRA 21-1 level, and
(12) surgical resection or not. Histological classification was
carried out according to five subgroups: adenocarcinoma,
squamous cell carcinoma, bronchioloalveolar carcinoma, adenos-
quamous carcinoma and large cell carcinoma. Due to the low
frequencies of both bronchioalveolar carcinoma and adenosqua-
mous carcinoma (four and seven respectively), these histological
subgroups were arbitrarily classified in the adenocarcinoma group.
Therefore, only three histological modalities were analysed. Some
centres prolonged their database accrual after their referred
publications. The most updated accrual was taken into account.
Statistical considerations
Survival was defined as the time from date of pretreatment serum
CYFRA 21-1 sampling to the date of death. Death related to the
disease whichever the progression site, or related to its treatment,
was analysed as an event. Deaths from other causes were treated as
censored observations. Survival distribution was estimated by the
Kaplan and Meier (1958) method. Univariate survival analyses
were carried out by means of log-rank tests.
Coding methods for the different variables depended on their
nature. Some of the variables have been extensively described in
the literature; therefore, the threshold has been defined from
previous publications. Performance status has been analysed
according to two classical modalities: PS 0-1 and PS greater than
or equal to 2 (Zubrod et al, 1960). Stage has been coded according
to the following three modalities: Ia–IIb, IIIa–IIIb and IV.
Regarding the tumour marker (CYFRA 21-1), we used the first
published threshold: 3.6ngml
 1 (Pujol et al, 1993a). Histology has
been coded according to the three aforementioned subgroups. Age
was dichotomously tested as younger or older than the median age
(63 years). The treatment modality was not tested as a prognostic
variable inasmuch as treatment was decided according to each
institution’s procedure and was based upon the different pretreat-
ment variables.
The date of origin of each database ranged from 23 February
1990 for the oldest to 2000 (seventh centre) for the newest. This
long period led to great differences in median follow-up from one
institution to another (Table 1), which precluded any definition of
a unique time of survival update for all patients. Therefore,
Table 1 Database description
Institution Centre Accrual Median follow-up (months) CYFRA 21-1 test Reference
Montpellier Acad. Hosp. 1 650 78 IRMA Pujol et al (2001a)
Heidelberg Acad. Hosp. 9 439 56 ELISA Ebert et al (1997)
Marseille Acad. Hosp. 2 291 50 IRMA Hamzaoui et al (1997)
Cuneo Acad. Hosp. 7 180 27 IRMA Buccheri et al (2003)
Jules Bordet Cancer Institute. 6 122 73 IRMA Paesmans et al (1995)
Strasbourg Acad. Hosp. 3 116 25 IRMA Wieskopf et al (1995)
Grenoble Acad. Hosp. 4 105 37 IRMA Moro et al (1995)
Warsaw Acad. Hosp. 8 90 63 IRMA Szturmowicz et al (1996)
Paris Acad. Hosp. 5 70 73 IRMA Brechot et al (1997)
IRMA¼immunoradiometric assay (Cis bio international, Gif/Yvette, France); ELISA¼enzyme-linked immunosorbent assay (Roche formely Boerhiner Mannhein, Germany).
Table 2 Summary of studies not included in the meta-analysis
CYFRA 21-1 predictive prognostic significance
Authors Year CYFRA 21-1 test Accrual Histology Stage Univariate Multivariate
Giovanella 1995 IRMA 148 All NSCLC All Significant NA
Takei 1997 ELISA 87 All NSCLC IIIB–IV Significant NA
Hirashima 1998 ELISA 149 All NSCLC All Significant Independent
Niklinski 1998 IRMA 94 All NSCLC Operable Significant Independent
a
Nisman 1998 and 1999 ELISA 116 All NSCLC All Significant Independent
Foa 1999 IRMA 62 All NSCLC Operable Significant Independent
Kashiwabara 2000 ELISA 108 SQC All Significant NA
NSCLC¼non-small-cell lung cancer ; SQC¼squamous cell carcinoma; NA¼not available. Total accrual: 764.
aAdjusted and stratified log-rank test on TNM stage.
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lpredefined time end points were used as fixed censored dates for
repeated analyses. For the whole population time end points were 1
year and 18 months: for inoperable patients 1 year only, for
operable patients 2 years only. In an attempt to determine
significant variables during the first year of follow-up, participa-
tion of each individual patient in the survival probability was
considered as true survival time for patients who died during this
first year of follow-up. Otherwise, patients were right censored at 1
year. Similar calculations were attempted for the subsequent time
end points (18 months and 2 years).
Multivariate regression was carried out with the Cox (1972)
model. The classical forward selection of variable procedure was
used. The selection of variables to be tested in the Cox model was
made using the results of univariate analysis, that is,. variables
reaching at least a p-level less than 15%. In addition, centre origin
was considered as a variable in order to detect a centre effect. This
model was written after a Boolean coding of the significant
variables except for stage grouping that was left as a three-
modality variable: categorical variables (such as performance
status) were transformed into binary variables (0: negative or 1:
positive). The number of levels of a Boolean variable needed to
describe a predictive factor is one less than the categories of that
factor inasmuch as its baseline level is defined by setting the value
of each of the Boolean variables at zero. The significance of the
effect of a given factor was assessed by determining whether or not
the coefficient assigned to one or more of its categories was
sufficiently different from zero. The proportional hazard assump-
tion for each of the selected variables retained in the final model
was originally checked by log minus log plots baseline hazard
ratio. This procedure demonstrated the proportionality of hazard
during the first 10-year period of follow-up and the first 18-month
period of follow-up for the whole population, and during the first 2
years for patients who underwent surgery. For the subsequent time
end points, the proportional hazard assumption was not verified
which precluded Cox model analysis. The high number of events
occurring during the first year of survival, and consequently the
lower number of patients at risk following this landmark, was the
explanation for the lack of proportionality. A p-level of less than
0.05 was considered significant. BMDP software package was used.
RESULTS
Patients’ characteristics
In total, 2063 NSCLC patients were accrued by nine institutions
(Table 1). Among them 75 (3.6%) were lost to follow-up. The
median follow-up varied from 6 years 7 months for Montpellier
Academic Hospital to 2 years 3 months for the Strasbourg
Academic Hospital. A total of 1616 events was recorded during
follow-up (78% of the patients). Characteristics of the global
population are shown in Table 3. The median age was 63 years and
therefore chosen as a threshold in order to analyse survival
according to this parameter. Female gender (16%) was under-
represented in comparison with the current sex ratio of NSCLC
populations included in North American or recent European
studies; a similar observation could be made for nonsquamous
histologies (adenocarcinoma and large-cell carcinoma), which
represented only one half of the population. Induction treatment
(surgery vs chemotherapy or radio-chemotherapy) was fully
recorded in all centres except one. A high serum CYFRA 21-1 level
was detected in approximately one half of the whole population, a
result in agreement with most of the individual studies.
Whole population survival analysis (1 year and 18 months)
Patients with a high serum CYFRA 21-1 level at time of
presentation proved to have a shorter survival when compared
with patients having a normal serum value (Figure 1). Additional
univariate analysis demonstrated a significant negative effect of the
following features: an advanced stage, a performance status of 2 or
higher, and age older than 63 years (Po10
 4 for all log-rank tests).
Histological subgroup and gender were not significant determi-
nants of prognosis.
In the multivariate analysis performed at the 1 year end-point
(Table 4; Figure 2), CYFRA 21-1 was a prognostic determinant in
Table 3 Patients’ characteristics
Variables
Median age (interquartile) 63 (54.9–69.0)
Sex: number (rate)
Male 1740 (0.84)
Female 323 (0.16)
Performance status (PS): number (rate)
PS0 378 (0.18)
PS1 682 (0.33)
PS2 474 (0.23)
PS3 197 (0.10)
PS4 57 (0.03)
PS not available 275 (0.13)
Stage group: number (rate)
Ia–Ib 209 (0.102)
Iia–Iib 108 (0.052)
IIIa 287 (0.139)
IIIb 563 (0.273)
IV 886 (0.429)
Stage not done 10 (0.005)
Histology: number (rate)
SQC 1039 (0.50)
ADE 721 (0.35)
LCC 303 (0.15)
Induction treatment: number (rate)
Surgery 437 (0.21)
No surgery 1521 (0.74)
Not known 105 (0.05)
CYFRA 21-1: number (rate)
p3.6ngml
 1 1049 (0.51)
43.6ngml
 1 1014 (0.49)
SQC¼squamous cell carcinoma; ADE¼adenocarcinma; LCC¼large cell carcino-
ma.
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Figure 1 Probability of survival of non-small-cell lung cancer patients
with normal and elevated pretreatment serum CYFRA 21-1 level; Kaplan–
Meier curves were constructed taking into account the whole population
survival.
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leach centre and reached statistical significance in eight out of nine
centres. The overall hazard ratio (95% confidence interval) was
1.88 (1.64–2.15), Po10
 4. Among the main classical prognostic
factors, stage of the disease and performance status were both
determinants of prognosis. In most of the centres both variables
matched the criterion of statistical significance: performance status
was a significant variable in five out of nine centres and stage
grouping in six out of nine centres, one of them having a definite
trend towards statistical significance (P¼0.05). Therefore, PS and
stage were less constant significant determinants when compared
with the prognostic effect related to the high serum CYFRA 21-1
level. Although age was not a statistically significant prognostic
determinant in a majority of centres, the overall evaluation
demonstrated that an age older than 63 years indicated a
poor prognosis (1.26 (1.11–1.44), P¼4 10
 4). Finally, there
was a indubitable trend towards a significant centre effect
as demonstrated by a hazard ratio of 1.02 (0.99–1.04) with a
P-value of 0.05.
Within the first 18-month period, proportional hazard
assumption was not verified for all variables in some centres.
Overall, that precluded the definition of the hazard ratios for
age and performance status. Nevertheless, the determination of
hazard ratio of risk of death for patients having a high
pretreatment CYFRA 21-1 level was possible inasmuch as the
proportional hazard assumption was verified in all centres except
one. Overall, the hazard ratio was in the range of the one calculated
within the first year of follow-up: 1.62 (1.42–1.86), Po10
 4
(Table 5 and Figure 3). Similarly, patients with an advanced stage
were affected by a higher risk of death. No centre effect
was disclosed in the proportional hazard model (HR¼1.00
(0.98–1.03), P¼0.63).
Survival analysis at one year for patients who did not
undergo surgery
The 1-year survival is considered as an important end point in
clinical trials of chemotherapy in advanced NSCLC. Therefore, the
Cox proportional hazard model was run again in patients who did
not undergo surgery (n¼1521). Proportional hazard assumption
was matched in each centre for all variables that reached the
statistical significance in univariate analysis (age, CYFRA 21-1,
stage grouping and performance status). No centre effect was
disclosed by the procedure: HR¼1.02 (0.99–1.05), P¼0.073. All
four variables were independent determinants of prognosis: age:
HR¼1.15 (1.00–1.33), P¼0.044; CYFRA 21-1: HR¼1.78 (1.54–
2.07), Po10
 4; stage grouping: HR¼1.33 (1.18–1.50), Po10
 4;
performance status: HR¼2.01 (1.75–2.33), Po10
 4.
Survival analysis at 2 years for patients having undergone
surgery
When the analysis was restricted to the 2-year survival rate in the
surgically treated population the proportional assumption was
verified for all variables and in all centres (n¼437). No centre
effect was disclosed (HR¼1.04 (0.98–1.09), P¼0.16). An ad-
vanced clinical stage (beyond stage IIb) remained the independent
prognostic determinant of a poor survival (HR: 1.42 (1.1–1.83)
P¼5 10
 3). A high pretreatment CYFRA 21-1 level also
indicated a poor outcome although the hazard ratio did not reach
the criterion of statistical significance, probably as a result of the
smaller size of this subgroup. A definite trend towards statistical
significance was observed, however (HR¼1.41 (0.99–2.03),
P¼0.055).
DISCUSSION
This meta-analysis aimed at accurately determining the hazard
ratio of risk of death for NSCLC patients having a high
pretreatment serum CYFRA 21-1 level compared to the group
having a normal level. The Cox proportional hazard model was run
at different predefined time end points, chosen according to their
clinical significance. Considering the whole population, the overall
Table 4 Results of Cox proportional hazard model within the first year of follow-up for the whole population
Age CYFRA 21-1 Stage grouping PS
Centre HR 95 CI P HR 95 CI P HR 95 CI P HR 95 CI P
Montpellier 1.22 (0.99–1.50) 0.047 1.69 (1.37–2.09) o10
 4 1.59 (1.32–1.91) o10
 4 1.87 (1.52–2.31) o10
 4
Heidelberg 1.30 (0.87–1.94) 0.1 1.91 (1.26–2.90) o10
 4 1.34 (1.00–1.80) 0.05 1.44 (0.96–2.15) 0.07
Marseille 0.88 (0.61–1.27) NS 2.22 (1.54–3.23) o10
 4 1.40 (1.00–1.94) 0.04 2.77 (1.74–4.42) o10
 4
Cuneo 0.79 (0.41–1.52) NS 1.52 (0.84–2.74) NS 1.22 (0.82–1.81) NS 2.27 (1.25–4.14) 6 10
 3
Bruxelles 1.56 (0.95–2.56) 0.07 1.93 (1.19–3.13) 6 10
 3 1.63 (0.83–3.18) NS 2.36 (1.25–4.43) 3 10
 3
Strasbourg 1.11 (0.60–2.05) NS 2.20 (1.07–4.52) 0.028 1.56 (0.89–2.76) NS 3.23 (1.77–5.91) o10
 4
Grenoble 2.70 (1.56–4.67) 2 10
 4 2.04 (1.18–3.52) 9 10
 3 1.4 (1.00–1.97) 0.04 1.61 (0.93–2.81) 0.08
Warsaw 0.93 (0.53–1.65) NS 1.72 (1.03–2.88) 0.034 1.72 (1.04–2.85) 0.03 1.38 (0.79–2.38) NS
Paris 2.80 (0.97–7.92) 0.05 4.61 (1.64–12.7) 3 10
 3 3.13 (1.46–6.69) 3 10
 3 1.74 (0.61–4.96) NS
Overall 1.26 (1.11–1.44) 4 10
 4 1.88 (1.64–2.15) o10
 4 1.41 (1.28–1.56) o10
 4 2.01 (1.76–2.30) o10
 4
Codage of variables: all codages were binary except for stage grouping. Age: median age according to calculation in each centre. HR calculated in patients’ aged more than median
age. CYFRA 21-1: HR affecting patients with a pretreatment serum CYFRA 21-1 level 43.6ngml
 1. Performance status according to Zubrod ECOG system. HR affecting
patients with a PS 2. Stage grouping according to the Mountain classification. This variable has been tested according to three modalities: Ia–IIb, IIIa–IIIb, and IV.
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Heidelberg Acad. Hosp.
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02 13 4 5 6
High CYFRA 21-1 level better High CYFRA 21-1 level worse
12.72
1 year
Figure 2 Hazard ratios and 95% confidence interval of mortality within
the first year of follow-up for NSCLC patients who presented with a high
pretreatment serum CYFRA 21-1 level. Results are expressed as individual
and overall hazard ratios (vertical bars), and their respective 95%
confidence intervals (horizontal bars). Hazard ratio higher than 1 indicates
an increased risk of death for patients affected by a high serum CYFRA 21-
1 level (Pp10
 4).
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21-1 level was 1.88 (1.64–2.15) and 1.62 (1.42–1.86) during the
first year and the first 18 month follow-up periods, respectively.
For patients who did not undergo surgery, the hazard ratio within
the first year was 1.78 (1.54–2.07) whereas for patients who
underwent surgery the hazard ratio within the first 2 years was 1.41
(0.99–2.03).
The unfavourable prognostic significance of a high serum
CYFRA 21-1 level was demonstrated at the early clinical
development of this tumour marker. Following the first publica-
tions (Ebert et al, 1993; Pujol et al, 1993a), many confirmatory
studies have been performed. Comprehensiveness is an important
methodological issue when making a meta-analysis. It requires the
amalgamation of all individual studies whatever the way of
subsequent scientific communication (publication or meeting
presentation). In the present meta-analysis, we made every effort
to comply with the comprehensiveness requirement by individual
contact with investigators and exhaustive publication research.
Unfortunately, some databases were not eligible for meta-analysis;
therefore, we present herein a population consisting of 73% of the
estimated accrual of all trials whatever the methodology and
reliability of databases. Contrasting with meta-analyses of clinical
treatment trials, our meta-analysis belongs to a pattern of
publications dealing with the prognostic significance of CYFRA
21-1. These prognostic studies are remarkable for their methodo-
logical heterogeneity. Differences in database reliability could be
the result of the prospective or retrospective nature of the study.
Important issues in this setting are organisation of the data
collection, type of dosage, blindness of the biological measure-
ments in order not to interact with clinical evaluation and
treatment decision. Avoiding an important bias consists in taking
treatment decision without knowledge of the studied variable. The
nine databases that have been amalgamated herein comply with
the best standards of prognostic study.
Due to the heterogeneity of follow-up duration from one study
to another, a formal evaluation of survival needs the preplanned
definition of time end points such as the 1-year survival rate in
inoperable patients and the 2-year survival rate in patients who
were operated upon. Consequently, the herein meta-analysis did
not allow the determination of prognostic variables of long-term
survival even though the median follow-up for the whole database
was long enough. Significant variables have been determined
considering participation of each individual patient. This method
allows the amalgamation of databases, which differ according to
the length of follow-up duration. The reliability of the statistical
procedure could therefore be ascertained.
A limit of this meta-analysis consisted of the lack of
homogeneity of staging procedure among the different centres.
For this reason we considered that subgroup analyses according to
stage grouping would have been unreliable. However, surgery was
undergone in each centre according to recognised guidelines (Ihde
et al, 1997). The same guidelines were used in proposing medical
treatment to patients suffering from unresectable disease, parti-
cularly chemotherapy regimens. Best supportive care was pro-
posed to patients with extremely poor performance status (13% of
the overall population). We therefore dichotomised the meta-
analysis into two subgroups: patients who underwent a complete
surgical resection and patients who were not eligible for surgery
and who received medical treatment only. The rationale for such a
dichotomisation is based on day-to-day clinical practice. The
prognostic significance of a high serum CYFRA 21-1 level was
observed in both groups. In addition, multivariate analysis
performed in the whole population demonstrated that both stage
and serum CYFRA 21-1 level were independent prognostic
determinants. Another point that could be discussed is the analysis
of survival at 2 years for patients who underwent surgery. We were
compelled to use this time end point in consideration of the major
heterogeneity in follow-up duration from one centre to another.
Finally, in the literature, the effect of age on NSCLC outcome has
been evaluated using different cutoffs, the 70 year cutoff having
been the most extensively used (Albain et al, 1991). Conflicting
results have been reported. In our study we decided arbitrarily to
use the median age (63 years) as the threshold. The effect of age on
Table 5 Results of Cox proportional hazard model within the first 18-month follow-up period for the whole population
Age CYFRA 21-1 Stage grouping PS
Centre HR 95 CI P HR 95 CI P HR 95 CI P HR 95 CI P
Montpellier 1.20 (0.99–1.46) 0.053 1.48 (1.22–1.80) o10
 4 1.47 (1.25–1.74) o10
 4 z NA
Heidelberg 0.96 (0.65–1.41) NS 1.55 (1.04–2.32) 0.03 1.55 (1.14–2.10) 4 10
 3 z NA
Marseille 0.75 (0.52–1.08) NS 2.04 (1.42–2.92) o10
 4 1.43 (1.09–1.89) 0.01 3.89 (2.38–6.34) o10
 4
Cuneo 0.82 (0.42–1.6) NS 1.44 (0.79–2.60) NS 1.24 (0.83–1.87) NS z NA
Bruxelles z NA z NA 1.86 (0.98–3.47) 0.052 1.61 (0.9–2.85) 0.1
Strasbourg z NA 1.92 (1.04–3.53) 0.03 1.65 (1.02–2.67) 0.04 2.78 (1.56–4.93) 4 10
 4
Grenoble 1.98 (1.12–3.49) 0.016 2.21 (1.28–3.81) 4 10
 4 1.42 (1.02–1.98) 0.04 1.45 (0.86–2.43) 0.16
Warsaw 0.86 (0.64–1.56) NS 2.91 (1.67–5.08) 2 10
 4 1.12 (0.681.85) NS 2.18 (1.23–3.85) 6 10
 3
Paris 2.27 (0.97–5.37) 0.055 3.63 (1.47–8.92) 4 10
 3 4.16 (1.66–10.4) 3 10
 3 1.17 (0.35–3.9) 0.79
Overall z NA 1.62 (1.42–1.86) o10
 4 1.43 (1.30–1.56) o10
 4 z NA
Codage of variables: All codages were binary except for stage grouping. Age: median age according to calculation in each centre. HR calculated in patients’ aged more than
median age. CYFRA 21-1: HR affecting patients with a pretreatment serum CYFRA 21-1 level 43.6ngml
 1. Performance status according to Zubrod ECOG system. HR
affecting patients with a PS 2. Stage grouping according to the Mountain classification. This variable has been tested according to three modalities: Ia–IIb, IIIa–IIIb, and IV. z
Proportional hazards assumption not verified.
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Figure 3 Hazard ratio and 95% confidence interval of mortality within
the first 18-month follow-up period for NSCLC patients who presented
with a high pretreatment serum CYFRA 21-1 level (symbols as in Figure 2;
Pp10
 4). Results from the Jules Bordet Institute were not presented
insofar as the proportional hazard assumption was not verified for these
variables during the first 18-month period.
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lsurvival was observed in the whole population, but this result is
restricted to our study and cannot be inferred to the general
population of patients suffering from NSCLC.
The case of CYFRA 21-1, as a prognostic marker of NSCLC,
might be discussed with regard to other putative tumour markers.
A simple classification of tumour markers could be as follows: (i)
oncofeotal markers and adhesion molecules: these markers are
typical indicators of cancer phenotype (e.g. carcinoembryonic
antigen); (ii) markers of cell lineage differentiation (CYFRA 21-1
belongs to this group of markers by detecting the epithelial
lineage); (iii) markers of cell proliferation (e.g. thyrosine kinase);
and finally, (iv) functional tumour markers. The last category
includes important signalling pathways toward cell proliferation,
cell differentiation, metastatic properties, antiapoptotic activity
and angiogenesis. This field is in exponential growth as it is in
close relationship with new targeted therapy approaches; adhesion
molecules, extracellular-domain of epidermal growth factor
receptor (ErbB 1) or Erb2 (HER2/neu), anti-p53 antibodies, belong
to the functional tumour marker category.
Carcinoembrionic antigen (CEA) is a 180kDa transmembrane
glycoprotein belonging to the immunoglobulin superfamily. CEA
is a complex of CEA itself, nonspecific cross-reacting antigen
(NCA), and biliary glycoprotein 1. All genes belonging to this
family are localised on chromosome 19 (Zimmermann et al, 1988).
In this view, NCA constitutes the most prominent CEA immunor-
eactive molecule. In lung cancer cell lines, CEA is involved as a
Ca
2þ-independent adhesion molecule in homotypic and hetero-
typic cell–cell binding. The CEA has been widely investigated as a
serum tumour marker of many human malignancies, including
lung cancer (Buccheri et al, 1987). Although its serum level is
correlated with tumour stage in both small cell and NSCLC, its
ability to help the prognostication and management of lung cancer
is controversial.
Neural cell adhesion molecules (NCAM) are likely to be involved
in the progression of lung cancer and, above all, in the phenotypic
diversification of NSCLC. They are sialylated glycoproteins
belonging to the immunoglobulin superfamily (Michalides et al,
1994). Their physiological role has been widely investigated and it
is now well-recognised that NCAM are important molecules in the
homotypic cell–cell relationship during the embryonic develop-
ment of the brain. NCAM are composed of an intracellular domain
and a transmembrane and extracellular domain. A single gene
localised on 11q23 chromosome codes for all types of the NCAM
family and alternative splicing of the large RNA segment result in
different isoforms of NCAM which differ by their molecular weight
(between 115 and 180kDa). Above all, post-transcriptional
modification of the molecule results in different NCAM
characterised by the length of an a2,8 polysialic acid (PSA)
chain linked-up to the extracellular domain of the molecule.
This PSA branch is strikingly involved in the negative regulation
of cell–cell adhesion. There is a concordant corpus of evidence
that lung cancer is affected by a wide phenotypic heterogeneity.
Non-small-cell lung cancer expresses the NCAM with a frequency
of up to 20% of NSCLC specimens (Pujol et al, 1989).The
heterotopic NCAM expression at the cell surface of NSCLCs has
added a new observation to the list of evidence that the lung cancer
phenotype of some tumours transgresses the frontier conveniently
introduced between small cell and NSCLC. Several retrospective
studies have been conducted in order to determine whether or not
NCAM expression yields a more aggressive clinical behaviour
(Berendsen et al, 1989) According to these studies, patients
suffering from NSCLC with NCAM expression proved to have a
shorter survival than those with a negative one. However, Cox
model multivariate analysis revealed that nodal status and
histology were the main independent determinants of prognosis
(Pujol et al, 1993b).
p53 remains a major tumour suppressor gene inasmuch as
its mutations result in an important step in lung cancer
carcinogenesis (Miller et al, 1992). p53 mutations occur in
all histological types at a frequency of 50–70%. There is a
rationale to consider p53 as a putative prognostic factor of lung
cancer: From a theoretical point of view, the p53 mutation
resulting in an inactive protein leads to lack of control of cell
proliferation by inhibiting the cell cycle arrest in the Gap 1 phase.
Thus, tumour cells expressing this phenotype (abnormal p53
protein) are known to be genetically unstable (Kuerbitz et al,
1992). As this last feature is associated with cell diversification and
tumour progression, it is tempting to analyse p53 mutation as a
prognostic factor. Detection of anti-p53 antibodies in the serum
has been proposed as a tumour marker for lung cancer. The
rationale for this detection is based upon the observation that
mutant p53 proteins accumulate and elicit immune reaction. In
addition, the detection of serum anti-p53 Ab is highly specific to
cancer. However, the test remains difficult to interpret and
conflicting results have arisen from the literature (Murray et al,
2000; Zalcman et al, 2000).
Considerable attention is currently paid to the erbB family of
receptor tyrosine kinases. There are four major identified
receptors: HER1 (EFGR), HER2, HER3 and HER4. Ligands that
interact with the extracellular domain are known for all members
of the family except HER2. The latter, however, seems to play a key
role in the process of heterodimerisation of the receptors, which in
turn activates the intracellular tyrosine kinase domain towards cell
proliferation, cell migration, angiogenesis, etc. HER-2/neu over-
expression in tissue could be associated with cleavage of the
extracellular domain. An ELISA method has been developed in
order to detect the extracellular domain (monoclonal for capture;
and polyclonal for detection). In a recent study, 84 patients with
advanced NSCLC receiving CDDP-based regimen were analysed
regarding the presence in the serum of the extracellular domain of
HER-2/neu. According to the Cox model, the presence of this
tyrosine kinase fragment is associated with a poor prognosis
(Ardizzoni et al, 2001). Whether or not this information could be
used in defining a population of patients candidate for anti HER-2/
neu therapy remains to be defined.
Up till now, there is no single study able to simultaneously
determine the respective prognostic significance of all aforemen-
tioned tumour markers. Therefore, it is not possible to establish
whether or not the detection of serum cytokeratin 19 fragment
(sequences 311–335 and 346–367) could be considered as better
or equivalent to prognostic determinants of NSCLC when
compared with the other new markers. Among the possible
advantage of CYFRA 21-1 one can point out, the complete
characterisation of the detected antigen, the knowledge of the
function of cytokeratin, the well-established accuracy and relia-
bility of the immunoradiometric assay and the large clinical
evaluation of the marker in different clinical settings.
Most of the published or presented individual studies, including
those that did not fit the methodological criterion for being
included in the present study, reported a significant negative
impact of a high serum CYFRA 21-1 level on NSCLC survival. The
herein meta-analysis confirms this literature analysis and allows a
precise estimation of the hazard ratio related to the marker. The
congruence between the meta-analysis procedure and the indivi-
dual reports strongly suggest that this is a true prognostic
determinant.
Once having considered the reliability of the prognostic
information and having measured the size of the effect on risk
of death, the next step would be to determine how to integrate
this information into therapeutic decision. Although of paramount
importance, this question could not be answered in our
study. Recently, the International Adjuvant Lung Trial
(Le Chevalier, 2003) demonstrated that adjuvant chemotherapy
after surgical resection of NSCLC induces a 4.1% absolute benefit
at 5 years for overall survival. A putative field of applicability
for pretreatment serum CYFRA 21-1 level titration would be
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lto determine whether or not patients with a high level have a
greater chance to benefit from this adjuvant therapy or whether
there is need for a more aggressive multimodality treatment
approach for these patients.
As of this moment, we conclude from our meta-analysis that
CYFRA 21-1 might be regarded as a putative co-variable in analysing
NSCLC outcome inasmuch as a high serum level is a significant
determinant of poor prognosis whatever the planned treatment.
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